Clinical trials: Antipsychotic
Schizophrenia
[18 Fluorine(F)]DOPA Determinants and Predictors of Treatment Response in Psychosis
The first purpose of this study is to determine if dopamine synthesis capacity is significantly lower in treatment non-responders from illness onset relative to treatment responders.
- Trial name
- DPTP (NCT02880995)
- Testing
- PET scan, clinical scale, 6 weeks of treatment with amisulpride
- Where
- 2 sites in South Korea
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Akathisia, Drug-Induced, Antipsychotic Agents
Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)
This study is designed to evaluate the effectiveness of preladenant in the prevention (Part 1) or treatment (Part 2) of antipsychotic induced akathisia in participants with acute psychosis using the Barnes Akathisia Scale.
- Conditions
- Akathisia, Drug-Induced, Antipsychotic Agents, Movement Disorders
- Trial name
- NCT00693472
- Testing
- Preladenant, Anticholinergic agents or propanolol, Haloperidol
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia
The TURNS is a National Institute of Mental Health (NIMH) funded contract for the evaluation of new compounds for the treatment of cognitive impairments in schizophrenia (HHSN 27820044 1003C; P.I.: Steve Marder, M.D.).
- Trial name
- NCT00425815
- Testing
- Org 24448
- Where
- 8 sites in United States
- Sponsor
- University of California, Los Angeles
Schizophrenia
Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia
The purpose of this study is to evaluate efficacy, safety and tolerance of long-acting risperidone when switching from oral antipsychotics in participants with schizophrenia (psychiatric disorder with symptoms of emotional…
- Trial name
- NCT01726335
- Testing
- Risperidone prolonged release
- Where
- 5 sites in Brazil
- Volunteers
- 53 people
- Sponsor
- Janssen-Cilag Ltd.
Schizophrenia
A Randomized, Double-blind, Comparison of the Efficacy and Safety of Amisulpride Versus Low-dose Amisulpride Plus Low-dose Sulpiride in the Treatment of Schizophrenia
Background: Surveys have shown that antipsychotic drug combinations are frequently prescribed. Amisulpride, an atypical antipsychotic agent, has low incidence of extrapyramidal symptom (EPS) but with high cost compared to…
- Trial name
- NCT01615185
- Testing
- full-dose amisulpride
- Where
- Taiwan
- Volunteers
- 96 people
- Sponsor
- Kaohsiung Kai-Suan Psychiatric Hospital
Schizophrenia
Quality of Life in Schizophrenic Patients
This is a non-interventional study evaluating quality of life in schizophrenic patients treated with atypical antipsychotics, in the ambulatory setting. This is a 9-month, observational, multicentric prospective study.
- Trial name
- Quality (NCT00597168)
- Where
- 45 sites in Belgium
- Volunteers
- 124 people
- Sponsor
- AstraZeneca
Hyponatremia, SIADH
Hyponatraemia and Mortality in Schizophrenic and Bipolar Patients: Protocol for a Bayesian Causal Inference Study
This study seeks to investigate if hyponatraemia be a direct contributor to death in schizophrenic and bipolar patients, and gauge the potential role of somatic comorbidity and psychotropic polypharmacy, with emphasis on…
- Trial name
- NCT04409626
- Testing
- Plasma sodium level (continuous variables)
- Volunteers
- 31,740 people
- Sponsor
- Zealand University Hospital
Dementia
Improving Well-being and Health for People With Dementia
800,000 people in the United Kingdom (UK)have dementia, of which 250,000 are living in care homes. These individuals have complex mental health problems, disabilities and social needs, which if unmet will continue to adversely…
- Trial name
- WHELD (NCT01855152)
- Testing
- Optimised WHELD intervention, Treatment as usual
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- professor Clive Ballard
Schizophrenia
A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
The primary objective of this study was to assess time to discontinuation due to lack of tolerability among patients with schizophrenia receiving LY2140023, given orally twice daily for 24 weeks, versus those on atypical…
- Trial name
- NCT00845026
- Testing
- LY2140023, aripiprazole, olanzapine
- Where
- 23 sites in United States, Germany and 2 more
- Volunteers
- 261 people
- Sponsor
- Denovo Biopharma LLC
Neuroleptic-Induced Tardive Dyskinesia
Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia
We initiate a study with research grant from department of health and Taoyuan mental hospital and choose risperidone and olanzapine as study medications.
- Trial name
- NCT00621998
- Testing
- risperidone, olanzapine
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
Schizophrenia Spectrum and Other Psychotic Disorders, Periodontal Diseases
Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients
The aim of the present cohort retrospective study is to explore the effect of antipsychotics on periodontal health and the possible effect of antipsychotic-induced hyperprolactinemia as a risk factor for periodontal disease…
- Trial name
- NCT06040944
- Testing
- antipsychotic drugs inducing hyperprolactinemia
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Fayoum University
Schizophrenia, Affective Symptoms
Atypical Antipsychotics in the Treatment of Affective Symptoms of Schizophrenia in Hungary
This is a noninterventional observational study lead amongst psychiatrists, to assess the the overall status of schizophrenic outpatients with affective symptoms treated with atypical antipsychotics.
- Trial name
- AFFECT (NCT01534936)
- Where
- 53 sites in Hungary
- Volunteers
- 2,153 people
- Sponsor
- AstraZeneca
Schizophrenia
Evaluating Subjective Well-being in Schizophrenic Patients Treated With quetiapineXR® and Other Atypical Antipsychotics
To evaluate the QOL (subjective effectiveness) in patients with schizophrenia, treated with atypical antipsychotics.
- Trial name
- Xperience (NCT00689325)
- Where
- 37 sites in Netherlands
- Volunteers
- 158 people
- Sponsor
- AstraZeneca
Schizophrenia
Different Safety Profile of Risperidone and Paliperidone Extended-release
The main objective of this study was to assess subjective experiences related to secondary negative symptoms and cognitive performance in healthy volunteers in response to multiple doses of paliperidone ER and risperidone in a…
- Trial name
- NCT01284959
- Testing
- risperidone, paliperidone ER
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
Post-traumatic Stress Disorder (PTSD)
Discontinuing Psychotropic Medication Before Psychotherapy for PTSD
Post-traumatic stress disorder (PTSD) is commonly treated with trauma-focused psychotherapy, including prolonged exposure therapy and eye movement desensitization and reprocessing (EMDR).
- Trial name
- NCT07802158
- Volunteers
- 100 people
- Sponsor
- Academic Centre for Dentistry in Amsterdam
Schizophrenia Spectrum Disorders
Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity
Rates of obesity in patients with schizophrenia-spectrum disorder (SSD)s have reached epidemic proportions, with established contributing effects of antipsychotic (AP) medications.
- Trial name
- Sema (NCT05333003)
- Testing
- Semaglutide
- Where
- Canada
- Volunteers
- 92 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia
The purpose of this study is to investigate the effects of flexibly dosed Brexpiprazole monotherapy in the improvement of early-episode schizophrenia through the assessment of social functioning, efficacy, and tolerability.
- Trial name
- NCT02013622
- Testing
- Brexpiprazole
- Where
- 22 sites in United States
- Volunteers
- 49 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Mental Illness
Behavioral Intervention to Reduce Novel Antipsychotic Medication Health Risks
This study will evaluate the effectiveness of a cognitive behavioral treatment in reducing significant medical risk factors often associated with people who have a serious mental illness and are taking atypical antipsychotic…
- Trial name
- NCT00709345
- Testing
- Cognitive behavioral sessions, Time-matched attention control sessions
- Volunteers
- 333 people
- Sponsor
- Medical College of Wisconsin
Schizophrenia, Psychotic Disorders
Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
The primary objective is to compare effectiveness of ziprasidone treatment to current treatments (haloperidol, olanzapine or risperidone) measured by change in Brief Psychiatric Rating Scale (BPRS) scores versus baseline
- Trial name
- NCT00137020
- Testing
- ziprasidone
- Where
- 27 sites in Egypt, Greece and 7 more
- Volunteers
- 294 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders
Sex, Psychopharmacology, and Diabetes
The term sexual (SD) dysfunction covers conditions that prevent people from having a satisfactory sex life. SD is a frequent and sometimes debilitating complication of mental illness and a known adverse reaction to…
- Conditions
- Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Diabetes Mellitus, PreDiabetes
- Trial name
- SECRET (NCT05951660)
- Testing
- Educational intervention
- Where
- Denmark
- Volunteers
- 256 people
- Sponsor
- Zealand University Hospital